Decreased expression of MT1E is a potential biomarker of prostate cancer progression
Metrics: HTML 1217 views | ?
Rita Demidenko1, Kristina Daniunaite1,2, Arnas Bakavicius2,3, Rasa Sabaliauskaite2, Aiste Skeberdyte1,2, Donatas Petroska4, Arvydas Laurinavicius4,5, Feliksas Jankevicius2,5, Juozas R. Lazutka1 and Sonata Jarmalaite1,2
1Life Sciences Centre, Vilnius University, Vilnius, Lithuania
2National Cancer Institute, Vilnius, Lithuania
3Urology Centre, Vilnius University, Vilnius, Lithuania
4National Centre of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
5Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Sonata Jarmalaite, email: email@example.com
Keywords: prostate cancer, biochemical recurrence, gene expression, MT1E
Received: November 15, 2016 Accepted: May 22, 2017 Published: June 27, 2017
Differentiation of indolent and aggressive prostate carcinoma (PCa) at the time of diagnosis is currently one of the major challenges. This study aimed at identification of prognostic biomarkers to aid in predicting biochemical recurrence (BCR) of the disease. Microarray-based gene expression profiling in tissues of 8 BCR and 8 No-BCR cases revealed expression differences of 455 genes, most of which were down-regulated in BCR cases. Eleven genes were selected for validation by real-time PCR in the first PCa cohort (N = 55), while seven of them were further validated in the second, independent, PCa cohort (N = 53). Down-regulation of MT1E (p < 0.001) and GPR52 (p = 0.002) expression and up-regulated levels of EZH2 (p = 0.025) were specific biomarkers of BCR in at least one of the two PCa cohorts, but only MT1E expression retained the independent prognostic value in a multivariate analysis (p < 0.001). DNA methylation analysis (114 PCa and 24 non-cancerous tissues) showed frequent MT1E methylation in PCa (p < 0.001) and was associated (p < 0.010) with the down-regulated expression in one PCa cohort. The results of our study suggest MT1E down-regulation as a potential feature of aggressive PCa.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.